Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Data for diabetic retinopathy treatment
November 2017
SHARING OPTIONS:

LEUVEN, Belgium—The European Association for Vision and Eye Research (EVER) 20th Annual Meeting saw ThromboGenics NV share preclinical data on THR-687 in a poster presentation titled “THR-687, a potent small molecule integrin receptor antagonist, holds promise as a therapeutic approach for back-of-the-eye vascular pathologies.” The data is from a study assessing the integrin-blocking and anti-angiogenic capabilities of THR-687, a novel small-molecule pan-RGD integrin antagonist. The compound is being developed to treat diabetic retinopathy, with or without diabetic macular edema.
 
Dr. Patrik De Haes, CEO of ThromboGenics, said “We are pleased to have this opportunity to present these preclinical data on THR-687 at the EVER meeting. THR-687 is one of four novel compounds we are developing for treatment of diabetic eye disease. The encouraging preclinical data we are presenting highlight our progress with THR-687, which is on track to enter the clinic in H1 2018.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.